Compare ARLO & MPLT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ARLO | MPLT |
|---|---|---|
| Founded | 2018 | 2018 |
| Country | United States | United States |
| Employees | N/A | 133 |
| Industry | Consumer Electronics/Appliances | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Staples | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.4B | 1.3B |
| IPO Year | 2018 | N/A |
| Metric | ARLO | MPLT |
|---|---|---|
| Price | $13.19 | $28.62 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 2 | 7 |
| Target Price | $24.00 | ★ $32.67 |
| AVG Volume (30 Days) | ★ 1.4M | 253.4K |
| Earning Date | 05-07-2026 | 05-28-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 145.16 | N/A |
| EPS | ★ 0.13 | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $9.29 | N/A |
| Revenue Next Year | $8.82 | N/A |
| P/E Ratio | $97.92 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $11.05 | $12.24 |
| 52 Week High | $19.94 | $33.28 |
| Indicator | ARLO | MPLT |
|---|---|---|
| Relative Strength Index (RSI) | 45.67 | 52.37 |
| Support Level | $11.64 | $26.70 |
| Resistance Level | $14.78 | $32.23 |
| Average True Range (ATR) | 0.78 | 2.34 |
| MACD | -0.10 | -0.40 |
| Stochastic Oscillator | 22.48 | 58.24 |
Arlo Technologies Inc is engaged in the provision of security and video monitoring solutions for homes and businesses. It combines a cloud infrastructure and mobile app with various smart connected devices to provide users with visibility, insight, and a means to help protect and connect in real-time with the people and things from any location with a Wi-Fi or a cellular connection. The company offers subscription services such as Arlo Secure, Arlo Total Security, and Arlo Safe, and several categories of smart security devices, including smart Wi-Fi and LTE-enabled cameras, video doorbells, floodlight cameras, and home security systems. Geographically, the company generates a majority of its revenue from the United States, followed by Spain, Sweden, and other countries.
MapLight Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing treatments for central nervous system disorders. Its discovery platform identifies neural circuits causally linked to disease and targets them for therapeutic modulation, aiming to improve efficacy, safety, tolerability, and ease of use. The company was founded by leaders in psychiatry and neuroscience research to address the lack of circuit-specific pharmacotherapies. Its product candidate, ML-007C-MA, is a fixed-dose combination of an M1/M4 muscarinic agonist and a peripherally acting anticholinergic, being developed for schizophrenia and Alzheimer's disease psychosis, designed to activate central receptors while mitigating peripheral side effects.